VX-765 is an inhibitor of NLRP3 inflammasome activity; it inhibits caspase 1 and IL-1β cleavage and release. VX-765 exhibits anti-inflammatory, antidepressant, and antiepileptic activities. In vivo, this compound decreases IL-1β levels and attenuates stress-induced depression-like behaviors. In animal models of status epilepticus, VX-765 decreases cell loss. In other similar animal models, this compound decreases chronic epileptic activity and delays onset of acute seizures.